| |
SWITCHING FROM ATAZANAVIR/RITONAVIR (ATV/RTV) TO ATV/COBICISTAT (COBI) IS ASSOCIATED WITH DECREASE OF PLASMA LIPIDS AND LIVER FIBROSIS
|
| |
| |
2018 HIV Glasgow
Reported by Jules Levin
A. Trentalange1, C. Polifroni1, C. Carcieri1, C. Alcantarini1, C. Montrucchio1, L. Marinaro1, N. Forni1, A. Palazzo1, A. Barco1, C. Costa1, A. Lazzaro1, M. Tettoni1, A. De Nicolò1, A. D’Avolio1, G. Di Perri1, A. Calcagno1, S. Bonora1
1. Unit of InfectiousDiseases, Department of MedicalSciences, Universityof Torino
Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia
Cobicistat versus Ritonavir as Pharmacoenhancers in Combination with Atazanavir Plus Tenofovir DF/Emtricitabine: Phase 3 Randomized, Double Blind, Active-Controlled Trial, Week 48 Results
References
1.Garcia G, Duenas C, Aleman Ana, et al. Lipid profile in HIV patients who switch from ritonavir to cobicistat. P1926. ECCMID21- 24 April 2018
2. Echeverria P, Bonjocj A, Puig J, et al. Significant improvement in triglyceridelevels afters witching from ritonavirto cobicistat in suppressed HIV-1-infected subject with dyslipidaemia. HIV Med. 2017 Nov; 18(10):782-786. doi: 10,1111/hiv. 12530, Epub2017 Jul3.
|
|
| |
| |
|
|
|
